Abbott labs India unit concludes recall of baby formula products manufactured at Michigan facility

Similac supplied in India is produced at Abbott's plant in the country's western state of Gujarat.

Published On 2022-05-21 06:21 GMT   |   Update On 2022-05-21 06:21 GMT

New Delhi: Abbott Laboratories' India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday."The voluntary recall in India impacted Alimentum and EleCare (brands). No other Abbott nutrition products, or Similac products, distributed in India were affected by...

Login or Register to read the full article

New Delhi: Abbott Laboratories' India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday.

"The voluntary recall in India impacted Alimentum and EleCare (brands). No other Abbott nutrition products, or Similac products, distributed in India were affected by the recall," the spokesperson told Reuters.

Abbott said earlier this week it had reached an agreement with the U.S. health regulator to resume production at the Michigan plant, which has been shut down over reports of bacterial infections in infants who had consumed products made at the facility. 

Read also: Abbott to release some nutrition products halted after baby formula recall

The company recalled dozens of types of Similac, Alimentum and EleCare powdered formulas in the U.S. and internationally following the infections. Similac supplied in India is produced at Abbott's plant in the country's western state of Gujarat.

The Food Safety and Standards Authority of India has been informed about the recall, according to the spokesperson.

The recall in February by Abbott in the United States created one of the most urgent food shortages in recent history for U.S. families, with other baby formula makers stepping up shipments to the country.

Read also: Presence of harmful bacteria at Similac production facility: USFDA probe

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News